CAPR Stock Skyrockets 144% in a Month: What Is Driving the Rally?

Capricor Therapeutics (CAPR) shares surged 144% over the past month following positive phase III HOPE-3 data showing a 54% reduction in upper-limb function decline for its deramiocel cell therapy in Duchenne muscular dystrophy. After an initial FDA rejection, the company refined its indication to focus on upper-limb function, and the FDA accepted the resubmission with a new PDUFA date of November 22, 2026. The stock rally reflects renewed investor optimism despite substantial regulatory risk.